Form 4: Cytokinetics EVP, Chief Commercial Officer Andrew Callos Sells Shares

Andrew Callos, EVP, Chief Commercial Officer of Cytokinetics Inc, sold 2,886 shares of common stock at a price of $35.78 on April 7, 2025.

Summary

• On April 7, 2025, Andrew Callos, the EVP, Chief Commercial Officer of Cytokinetics Inc, sold 2,886 shares of the company's common stock.
• The sale was executed at a price of $35.78 per share.
• Following the transaction, Mr. Callos directly owns 64,689 shares of Cytokinetics Inc.

Sentiment

Score: 5

Explanation: Neutral sentiment as it is a routine disclosure of an insider stock sale. The impact depends on the size and context of the sale.

Industry Context

This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company executives.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, but it is a common occurrence and doesn't necessarily indicate a negative outlook for the company.

Key Dates

Keywords

Cytokinetics Inc, Andrew Callos, stock sale, Form 4, CYTK, EVP, Chief Commercial Officer, insider trading